Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]
Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains [Yahoo! Finance]
Insmed shares rise on positive late-stage trial results for lung disease therapy [Yahoo! Finance]
Insmed (INSM) had its price target lowered by Wells Fargo & Company from $208.00 to $175.00. They now have an "overweight" rating on the stock.
S&P 500 Futures Rise in Premarket Trading; Insmed, Mobileye Global Lead [Barron's]